FCCC LOGO Faculty Publications
Abou-Nassar KE , Vanderplas A , Friedberg JW , Abel GA , Niland J , Rodriguez MA , Czuczman MS , Millenson M , Crosby A , Gordon LI , Zelenetz AD , Kaminski M , Lacasce AS
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database
Leukemia & Lymphoma. 2013 Oct;54(10) :2155-2162
PMID: WOS:000324589800014   
Back to previous list
Abstract
We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Patients who presented between 1 January 2001 and 30 September 2009 with newly diagnosed grade 1-2 FL, with at least 6 months of follow-up, were included. We identified 953 eligible patients and 532 (56%) underwent FDG-PET as part of initial staging. Among patients who underwent FDG-PET for initial staging, 438 (82%) received early treatment compared to 259 (61.5%) of those staged without FDG-PET (p < 0.0001). Of all patients with stage I FL (n = 100), 47% were treated with radiotherapy (RT) alone, and the choice of initial treatment strategy for stage I FL did not vary significantly by use of FDG-PET (p = 0.22). The use of FDG-PET for staging of FL is widespread and is associated with a greater proportion of patients receiving early therapy. Given the widespread use and high cost of FDG-PET, its clinical utility in stage I FL should be further evaluated.
Notes
Abou-Nassar, Karim E. Vanderplas, Ann Friedberg, Jonathan W. Abel, Gregory A. Niland, Joyce Rodriguez, Maria A. Czuczman, Myron S. Millenson, Michael Crosby, Allison Gordon, Leo I. Zelenetz, Andrew D. Kaminski, Mark Lacasce, Ann S.